share_log

In8bio | 424B5: Prospectus

In8bio | 424B5: Prospectus

In8bio | 424B5：募資說明書
美股sec公告 ·  05/07 16:14
Moomoo AI 已提取核心訊息
In8bio has filed a prospectus supplement with the Securities and Exchange Commission, amending its previous prospectus dated November 21, 2022. The supplement, dated May 7, 2024, allows for the offer and sale of up to $8,900,000 of In8bio's common stock under a Controlled Equity Offering with Cantor Fitzgerald & Co. as the Sales Agent. To date, In8bio has sold 8,392,204 shares for gross proceeds of approximately $15.9 million. The company is limited by General Instruction I.B.6 of Form S-3 in the amount it can sell, which currently stands at an aggregate offering price of up to $8,900,000, considering the current public float. In8bio's common stock is traded on the Nasdaq Global Market under the symbol 'INAB'. The market value of non-affiliate held common stock was $41.5 million as of May...Show More
In8bio has filed a prospectus supplement with the Securities and Exchange Commission, amending its previous prospectus dated November 21, 2022. The supplement, dated May 7, 2024, allows for the offer and sale of up to $8,900,000 of In8bio's common stock under a Controlled Equity Offering with Cantor Fitzgerald & Co. as the Sales Agent. To date, In8bio has sold 8,392,204 shares for gross proceeds of approximately $15.9 million. The company is limited by General Instruction I.B.6 of Form S-3 in the amount it can sell, which currently stands at an aggregate offering price of up to $8,900,000, considering the current public float. In8bio's common stock is traded on the Nasdaq Global Market under the symbol 'INAB'. The market value of non-affiliate held common stock was $41.5 million as of May 7, 2024, based on a closing price of $1.30 per share on March 8, 2024. In the past 12 months, In8bio has sold $4,926,024 worth of securities under the same instruction. The company cautions that investing in its securities involves high risk, advising investors to review the 'Risk Factors' section in the Prior Prospectus and its most recent financial reports.
In8bio已向美國證券交易委員會提交了招股說明書補充文件，修訂了其先前於2022年11月21日的招股說明書。該補編日期爲2024年5月7日，允許以坎託·菲茨傑拉德公司爲銷售代理的受控股權發行，發行和出售In8Bio高達890萬美元的普通股。迄今爲止，In8Bio已出售了8,392,204股股票，總收益約爲1,590萬美元。該公司可出售的金額受到S-3表格I.B.6號一般指令的限制，考慮到目前的公衆持股量，該公司的總髮行價最高爲8,900,000美元。In8bio的普通股在納斯達克全球市場上市，股票代碼爲 “INAB”。根據2024年3月8日每股1.30美元的收盤價，截至2024年5月7日，非關聯公司持有的普通股的市值爲4,150萬美元。在過去的12個月中，In8Bio根據同一指令出售了價值4,926,024美元的證券。該公司警告說，投資其證券涉及高風險，建議投資者查看先前招股說明書及其最新財務報告中的 “風險因素” 部分。
In8bio已向美國證券交易委員會提交了招股說明書補充文件，修訂了其先前於2022年11月21日的招股說明書。該補編日期爲2024年5月7日，允許以坎託·菲茨傑拉德公司爲銷售代理的受控股權發行，發行和出售In8Bio高達890萬美元的普通股。迄今爲止，In8Bio已出售了8,392,204股股票，總收益約爲1,590萬美元。該公司可出售的金額受到S-3表格I.B.6號一般指令的限制，考慮到目前的公衆持股量，該公司的總髮行價最高爲8,900,000美元。In8bio的普通股在納斯達克全球市場上市，股票代碼爲 “INAB”。根據2024年3月8日每股1.30美元的收盤價，截至2024年5月7日，非關聯公司持有的普通股的市值爲4,150萬美元。在過去的12個月中，In8Bio根據同一指令出售了價值4,926,024美元的證券。該公司警告說，投資其證券涉及高風險，建議投資者查看先前招股說明書及其最新財務報告中的 “風險因素” 部分。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息